Business context and reporting period
The supplied filing is Mainz Biomed N.V.’s annual report on Form 20-F for the fiscal year ended December 31, 2022—not a filing for “Quantum Cyber N.V.” and not a standalone Q4 report. The company develops and sells in-vitro diagnostic tests, principally ColoAlert, a colorectal cancer screening test marketed in Europe, and is researching PancAlert for pancreatic cancer. Financial statements are prepared under IFRS as issued by the IASB.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $529,877 | $577,348 |
| Gross profit / margin | $182,151 / 34.4% | $177,622 / 30.8% |
| Operating expenses | $26,691,580 | $9,902,228 |
| Operating loss | $(26,509,429) | $(9,724,606) |
| Net loss | $(26,387,336) | $(11,690,098) |
| Operating cash flow | $(14,769,590) | $(3,220,324) |
| Investing cash flow | $(658,483) | $1,203,151 |
| Financing cash flow | $23,943,418 | $10,610,534 |
| Cash at year-end | $17,141,775 | $8,727,542 |
ColoAlert revenue was $519,728 in 2022, up 130% from $226,438 in 2021. COVID-19 testing revenue ended: 2021 included $233,662, while 2022 had none. The company reported no income tax provision. EBITDA and a defined operating margin are not provided.
At December 31, 2022, total assets were $20.24 million, current assets $18.38 million, total liabilities $6.14 million, and shareholders’ equity $14.10 million. Current liabilities were $4.24 million. Liabilities included $1.91 million in silent partnerships, $75,238 in convertible debt, and $1.24 million in lease liabilities. Silent partnership agreements include stated interest and, in certain cases, additional maturity payments. The company raised $23.9 million net from share and warrant issuance in 2022, primarily through a January follow-on offering.
Material changes versus the prior period
- Revenue fell 8%, despite ColoAlert growth, largely because COVID-19 testing and research-use product sales ceased.
- Gross margin improved from 30.8% to 34.4%, attributed to stronger ColoAlert margins and the end of COVID-19 testing.
- Operating expenses increased 170%. Research and development rose to $3.66 million, sales and marketing to $5.70 million, and general and administrative expenses to $17.33 million.
- Net loss more than doubled. General and administrative expense included substantial share-based compensation; the cash flow statement added back $9.82 million of share-based compensation.
- Cash increased following equity financing, while operating cash use rose to $14.77 million. The company issued 1.725 million shares in January 2022 for $25.9 million gross proceeds and received $382,500 from warrant exercises.
Outlook, commentary and risks
Management expects most near-term revenue to come from ColoAlert and plans to expand European laboratory partnerships, pursue U.S. FDA market authorization, and continue PancAlert development. The filing gives no revenue, earnings, or cash-flow guidance. It describes a planned U.S. pivotal reconAAsense study of approximately 15,000 participants across 150 sites, with initiation targeted for the second half of 2023. ColoFuture and eAArly DETECT studies were intended to evaluate UdeS mRNA biomarkers for possible incorporation into a next-generation ColoAlert; study outcomes could affect product development and the pivotal study design.
The auditor’s report includes an explanatory paragraph stating substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and negative operating cash flows. Management said cash on hand and potential additional financing—including approximately $1.3 million of net proceeds from controlled equity sales after year-end—were expected to fund planned expenditures and obligations for at least one year after the financial statements’ issuance. The statements are nevertheless prepared on a going-concern basis. If funding is unavailable, the company may have to delay, reduce, or eliminate development, regulatory, and commercial efforts.
Key risks include limited revenue and continuing cash burn; dependence on ColoAlert; physician and patient adoption, reimbursement, and competition; lengthy and uncertain FDA and EU IVDR review; clinical-study performance and delays; customer concentration; dilution from future equity issuance; and currency exposure. The company disclosed no material litigation. In February 2023, after year-end, it acquired ColoAlert intellectual property for $2 million cash payable over four years, 300,000 restricted shares, and a revenue share capped at $1 per test for 10 years. It also acquired UdeS biomarker rights for €25,000 and a 2% net-sales profit share on products using them.
Important facts for investors to verify
- Confirm the issuer identity: the filing identifies Mainz Biomed N.V., whereas the request metadata names Quantum Cyber N.V.
- Review the going-concern disclosure, cash runway assumptions, post-year-end financing, and actual subsequent cash burn.
- Reconcile customer concentration disclosures: the business discussion says two customers accounted for 38% of 2022 revenue, while the financial statement note says three customers accounted for 77%.
- Track ColoAlert sales growth, gross margin, customer additions, reimbursement, and dependence on a limited number of laboratory customers.
- Monitor enrollment, results, timing, and costs of the clinical studies and progress toward FDA and IVDR authorization.
- Assess potential dilution, including outstanding warrants and options, and the costs and obligations under the ColoAlert and UdeS biomarker agreements.